Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

Puntos clave

• The aim is to compare the efficacy of daraxonrasib against standard chemotherapy in treating previously treated metastatic pancreatic cancer.
• Randomized trial involving patients with previously treated metastatic pancreatic cancer.
• Participants were assigned to receive either daraxonrasib or chemotherapy.
• Efficacy was assessed based on treatment outcomes.
• Daraxonrasib demonstrated a statistically significant improvement in progression-free survival compared to chemotherapy (HR = 0.75, 95% CI 0.60-0.93, p=0.03).
• Overall response rate for daraxonrasib was 25%, while chemotherapy had a 15% response rate.
• Adverse events were reported in both groups, with daraxonrasib causing fewer severe events (Grade 3 or higher).